Updated:
Wellington Partners
Wellington Partners is a private equity based in Munich, Bavaria, founded 1998, managing ~€800 million; the Altss profile covers its classification,...
Wellington Partners
Wellington Partners is an SEC-registered investment adviser based in Munich, Bavaria, established in 2000. It is registered with the SEC since 2000.
General information
Firm type
Private Equity
Year founded
1998
AUM
~€800 million
Location
Region
Europe
Country
Germany
City
Munich, Bavaria
Corporate office
Türkenstraße 5, 80333 Munich, Germany
Additional offices
Seidengasse 16, 8001 Zurich, Switzerland
Principals
Dr. Rainer Strohmenger
Managing Partner
Dr. Johannes Fischer
Managing Partner
Dr. Varun Gupta
Partner
Harald Keller
Managing Partner, CFO
Ernst Mannheimer
Managing Partner, Legal Counsel
Sabine Kannegiesser
Partner
Dr. Regina Hodits
Venture Advisor
Sector focus
Frequently asked questions
Who runs investment decisions at Wellington Partners?
Managing Partners Dr. Rainer Strohmenger and Dr. Johannes Fischer lead the investment team. Dr. Varun Gupta, Sabine Kannegiesser, and Venture Advisor Dr. Regina Hodits are also named as senior deal professionals. The firm's website lists no separate investment committee, suggesting decisions rest with the managing partner group.
Does Wellington Partners invest outside of Europe?
Wellington states it focuses on companies from Germany, Europe, and beyond. Its Zurich office and portfolio companies like Polares Medical, which is U.S.-focused, indicate the firm will back European-origin companies that pursue global regulatory pathways, including FDA approval in the United States.
Is Wellington Partners structured as a single family office or does it operate more like a venture firm?
Wellington Partners is a venture capital firm, not a family office. It manages multiple closed-end funds raised from external institutional investors and was founded as an independent asset manager in 1998. The firm's latest vehicle, WPLS V, closed at EUR 210 million and was described by the firm as considerably oversubscribed.
What investment stages does Wellington Partners typically target?
The firm targets early- and growth-stage life science companies. Its portfolio spans seed, Series A, and Series B rounds (such as the EUR 84 million Series B for NUCLIDIUM in July 2025 and the CHF 105 million total for the same company by May 2026), as well as later-stage expansion financings.
How is Wellington Partners' current fund different from its predecessors?
WPLS V, the firm's fifth fund, closed at EUR 210 million, which the firm reports is more than double the volume of its predecessor. It was considerably oversubscribed and remains focused on biotechnology and medical technology.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: